Recent advances in CD8+ T cell-based immune therapies for HIV cure

Arenas, Valentina Restrepo; Rugeles, Marı́a Teresa; Perdomo‐Celis, Federico; Taborda, Natalia A.

doi:10.1016/j.heliyon.2023.e17481

Cited by 1 publication

(1 citation statement)

References 169 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In HIV infection, T cells (and more specifically, CD8 + cytotoxic T cells) play a significant role in enhancing the immune response. This effect is evidenced not only by the association between various HLA class I alleles (expressed by most nucleated cells of the organism) and the control of HIV but also by the formation of HIV-specific CD8 + T cells with memory potential that decrease viremia early in infection [ 25 ]. Consistently, several T-cell immunotherapeutic approaches, specifically vaccines, cytokines, immune checkpoint blocking agents and CAR-T cells, are being studied for the treatment of HIV infection, as recently reviewed [ 25 ].…”

Section: Extending T-cell Engagers To Infectious Diseasesmentioning

confidence: 99%

Bridging the gap with multispecific immune cell engagers in cancer and infectious diseases

Rolin,

Zimmer,

Seguin-Devaux

2024

Cell Mol Immunol

View full text Add to dashboard Cite

By binding to multiple antigens simultaneously, multispecific antibodies are expected to substantially improve both the activity and long-term efficacy of antibody-based immunotherapy. Immune cell engagers, a subclass of antibody-based constructs, consist of engineered structures designed to bridge immune effector cells to their target, thereby redirecting the immune response toward the tumor cells or infected cells. The increasing number of recent clinical trials evaluating immune cell engagers reflects the important role of these molecules in new therapeutic approaches for cancer and infections. In this review, we discuss how different immune cell types (T and natural killer lymphocytes, as well as myeloid cells) can be bound by immune cell engagers in immunotherapy for cancer and infectious diseases. Furthermore, we explore the preclinical and clinical advancements of these constructs, and we discuss the challenges in translating the current knowledge from cancer to the virology field. Finally, we speculate on the promising future directions that immune cell engagers may take in cancer treatment and antiviral therapy.

show abstract

Section: Extending T-cell Engagers To Infectious Diseasesmentioning

confidence: 99%